Dublin, Dec. 07, 2018 (GLOBE NEWSWIRE) -- The "Global Statin Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.



The statin market will register a CAGR of over 2% by 2023.


The increasing statin use will help the market grow at a steady rate. In the US and the UK, people aged 40 and above are recommended to monitor their cholesterol level. Statins are considered an evidence-based treatment for high risk patients with elevated cardiovascular disorder.


Rising prevalence of hypercholesterolemia

The rising prevalence of hypercholesterolemia is fueling the demand for generic cholesterol medications. Cardiovascular disease is one of the primary causes of mortality in Western countries.

Fierce generic competition

Patient expiration is a major challenge for companies developing branded drugs as it provides an opportunity for the development of generic drugs.


Key Players

  • AstraZeneca
  • Merck
  • Novartis
  • Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Pipeline

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Synthetic statins - Market size and forecast 2018-2023
  • Natural statins - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION

  • Dyslipidemia
  • Others

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Merck
  • Novartis
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/p7wsvs/global_statin?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs